$14.17
-0.10[-0.70%]
Last update: 9:30AM Get Real Time Here
Immunome
(NASDAQ:IMNM)Immunome Stock (NASDAQ:IMNM), Analyst Ratings, Price Targets, Predictions
Immunome Inc has a consensus price target of $23.8, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from Guggenheim, Wedbush, and Wedbush on April 15, 2024, April 1, 2024, and January 23, 2024. With an average price target of $29 between Guggenheim, Wedbush, and Wedbush, there's an implied 102.44% upside for Immunome Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Wedbush
Cantor Fitzgerald
Chardan Capital
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Immunome
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/15/2024 | IMNM | Buy Now | Immunome | $14.32 | 144.33% | Guggenheim | Michael Schmidt | → $35 | Initiates | → Buy | Get Alert |
| 04/01/2024 | IMNM | Buy Now | Immunome | $14.32 | 130.37% | Wedbush | David Nierengarten | $27 → $33 | Maintains | Outperform | Get Alert |
| 01/23/2024 | IMNM | Buy Now | Immunome | $14.32 | 32.64% | Wedbush | David Nierengarten | $12 → $19 | Maintains | Outperform | Get Alert |
| 12/19/2023 | IMNM | Buy Now | Immunome | $14.32 | -16.23% | Wedbush | David Nierengarten | → $12 | Initiates | → Outperform | Get Alert |
| 03/20/2023 | IMNM | Buy Now | Immunome | $14.32 | -44.15% | Cantor Fitzgerald | Pete Stavropoulos | → $8 | Reiterates | → Overweight | Get Alert |
| 03/17/2023 | IMNM | Buy Now | Immunome | $14.32 | -44.15% | Chardan Capital | Matthew Barcus | $9 → $8 | Maintains | Buy | Get Alert |
| 10/29/2021 | IMNM | Buy Now | Immunome | $14.32 | 144.33% | Cantor Fitzgerald | Brian Cheng | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Immunome (IMNM)?
The latest price target for Immunome (NASDAQ: IMNM) was reported by Guggenheim on April 15, 2024. The analyst firm set a price target for $35.00 expecting IMNM to rise to within 12 months (a possible 147.00% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunome (IMNM)?
The latest analyst rating for Immunome (NASDAQ: IMNM) was provided by Guggenheim, and Immunome initiated their buy rating.
When was the last upgrade for Immunome (IMNM)?
There is no last upgrade for Immunome.
When was the last downgrade for Immunome (IMNM)?
There is no last downgrade for Immunome.
When is the next analyst rating going to be posted or updated for Immunome (IMNM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunome, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunome was filed on April 15, 2024 so you should expect the next rating to be made available sometime around April 15, 2025.
Is the Analyst Rating Immunome (IMNM) correct?
While ratings are subjective and will change, the latest Immunome (IMNM) rating was a initiated with a price target of $0.00 to $35.00. The current price Immunome (IMNM) is trading at is $14.17, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.